PT  - JOURNAL ARTICLE
AU  - Jackson, Sarah E.
AU  - Brown, Jamie
AU  - Shahab, Lion
AU  - Arnott, Deborah
AU  - Bauld, Linda
AU  - Cox, Sharon
TI  - Nicotine strength of e-liquids used by adult vapers in Great Britain: a population survey 2016 to 2024
AID  - 10.1101/2024.03.13.24304222
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.03.13.24304222
4099  - http://medrxiv.org/content/early/2024/03/15/2024.03.13.24304222.short
4100  - http://medrxiv.org/content/early/2024/03/15/2024.03.13.24304222.full
AB  - Background/Aims In March-2024, the UK government announced plans to introduce a new Vaping Products Duty that will tax e-liquids based on their nicotine strength. This study examined trends in the nicotine strength of e-liquids used by adult vapers and differences in those currently used across relevant subgroups.Design Nationally-representative, cross-sectional household survey, July-2016 to January-2024.Setting Great Britain.Participants 7,957 adult vapers.Main outcome measures Participants were asked whether the e-cigarette they mainly use contains nicotine and the e-liquid strength. We used logistic regression to estimate time trends in different nicotine strengths used (no nicotine/>0-≤6/7-11/12-19/≥20 mg/ml), overall in England and stratified by main device type (disposable/refillable/pod), age (≥18y), and smoking status. We explored current differences in nicotine strength among those surveyed between January-2022 and January-2024 in Great Britain by main device type, age (≥16y), gender, occupational social grade, history of ≥1 mental health conditions, smoking status, and (among past-year smokers) level of cigarette addiction.Results The proportion of vapers in England using high-strength (≥20mg/ml) e-liquids increased from an average of 3.8% [95%CI 2.9-5.0%] up to June-2021 to 32.5% [27.9-37.4%] in January-2024 (when 93.3% reported using exactly 20mg/ml). This rise was most pronounced among those using disposable e-cigarettes, those aged 18-24y, and all smoking statuses (including never smokers) except long-term (≥1y) ex-smokers. Of those surveyed in 2022-24 in Great Britain, overall, 89.5% [88.1-90.8%] said they usually used e-cigarettes containing nicotine, 8.7% [7.5-10.0%] used nicotine-free e-cigarettes, and 1.8% [1.2-2.4%] were unsure. The proportion using ≥20mg/ml was higher among those mainly using disposable (47.9%) compared with pod (16.3%) or refillable (11.5%) devices; never smokers (36.0%), current smokers (28.8%), or recent (<1y) ex-smokers (27.4%), compared with long-term ex-smokers (13.9%); and younger (16-24y; 44.2%) compared with older (≥25y; range 9.4-25.1%) age groups. There were no notable differences across other subgroups of interest.Conclusions Use of high-strength nicotine e-liquids in England has increased sharply in recent years. Most adult vapers in Great Britain use e-cigarettes that contain nicotine but different subgroups use different strengths: they tend to be higher among those who mainly use disposable devices, those aged 16-24y, and lower among long-term ex-smokers.Competing Interest StatementJB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, unrestricted research grants and travel expenses to attend meetings and workshops from manufactures of smoking cessation medications (Pfizer; J&J), and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare that they have never had any financial links with tobacco companies, e-cigarette manufacturers, or their representatives.Funding StatementThis work was supported by Cancer Research UK (PRCRPG-Nov21\100002).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the STS was granted originally by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymised when received by UCL.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available on Open Science Framework https://osf.io/gp9jv/